Lantus
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Lantus (insulin glargine; Sanofi) was the first long-acting basal insulin analog to reach the market. Originator Aventis launched it across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) between 2000 and 2003, prior to its merger with Sanofi. Lantus was originally indicated for the improvement of glycemic control in patients with type 1 or type 2 diabetes aged six years and older. In 2012, the European Medicines Agency extended Lantus’s pediatric indication to type 1 diabetes patients aged two years and older, further expanding the product’s target market.
Lantus is administered via a pen injector. Within the injection device, the product is soluble owing to the acidic environment. Neutralization of the acidic insulin glargine solution after subcutaneous injection results in the formation of micro-precipitates that slowly release small amounts of insulin. This gives rise to Lantus’s relatively constant concentration profile over 24 hours and no pronounced peak. Its long duration of action ensures the product can be used to treat both type 1 and type 2 diabetes in a basal-bolus regimen.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Lantus : Diabetes type 2
20 Lantus : Diabetes type 1
LIST OF FIGURES
9 Figure 1: Lantus brand franchise for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of Lantus
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for Lantus
13 Figure 4: Lantus sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
15 Figure 5: Soliqua sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
17 Figure 6: Toujeo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
23 Figure 7: Lantus for type 1 diabetes – SWOT analysis
24 Figure 8: Datamonitor Healthcare’s drug assessment of Lantus in type 1 diabetes
25 Figure 9: Datamonitor Healthcare’s drug assessment of Lantus in type 1 diabetes
LIST OF TABLES
5 Table 1: Lantus drug profile
6 Table 2: Overview of pivotal trial data for Lantus in type 2 diabetes
14 Table 3: Lantus sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
16 Table 4: Soliqua sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
18 Table 5: Toujeo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
21 Table 6: Lantus drug profile
22 Table 7: Lantus pivotal trial data in type 1 diabetes
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Levemir 
Sign up to the